Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules
- 14 September 2018
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 39 (1) , 265-301
Abstract
Cancer immunotherapy has made great strides in the recent decade, especially in the area of immune checkpoint blockade. The outstanding efficacy, prolonged durability of effect, and rapid assimilation of anti‐PD‐1 and anti‐PD‐L1 monoclonal antibodies in clinical practice have been nothing short of a medical breakthrough in the treatment of numerous malignancies. The major advantages of these therapeutic antibodies over their small molecule counterparts have been their high binding affinity and target specificity. However, antibodies do have their flaws including immune‐related toxicities, inadequate pharmacokinetics and tumor penetration, and high cost burden to manufacturers and consumers. These limitations hinder broader clinical applications of the antibodies and have heightened interests in developing the alternative small molecule platform that includes peptidomimetics and peptides to target the PD‐1/PD‐L1 immune checkpoint system. The progress on these small molecule alternatives has been relatively slow compared to that of the antibodies. Fortunately, recent structural studies of the interactions among PD‐1, PD‐L1, and their respective antibodies have revealed key hotspots on PD‐1 and PD‐L1 that may facilitate drug discovery efforts for small molecule immunotherapeutics. This review is intended to discuss key concepts in immuno‐oncology, describe the successes and shortcomings of PD‐1/PD‐L1 antibody‐based therapies, and to highlight the recent development of small molecule inhibitors of the PD‐1/PD‐L1 protein‐protein interaction.Keywords
This publication has 176 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- CTLA-4 Is a Direct Target of Wnt/β-Catenin Signaling and Is Expressed in Human Melanoma TumorsJournal of Investigative Dermatology, 2008
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptorsProceedings of the National Academy of Sciences, 2008
- Reaching for high-hanging fruit in drug discovery at protein–protein interfacesNature, 2007
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- Perforin Triggers a Plasma Membrane-Repair Response that Facilitates CTL Induction of ApoptosisImmunity, 2005